Isracann Biosciences Inc. (CSE:IPOT) has launched its campaign on the Investing News Network’s cannabis channel.

Isracann is an Israel-based cannabis company focused on becoming a premier low-cost cannabis producer. The company is developing its fully-funded 230,000-square-foot cultivation facility near Tel Aviv, Israel, and plans to target the undersupplied domestic and European markets. The facility is being built to ISL and EU-GMP standards, and the company is applying for IMC-GAP and GSP certification, which allows Isracann to export its products and brands into Europe. Once Isracann’s facility is complete, it is expected to have an annual capacity of 23,500 kilograms.

Israel is high in humidity and has ideal year-round temperatures, allowing Isracann to keep its production rates as low as C$0.40 per gram. The country also receives, on average, 300 days of sun per year and high UV rays, which contributes to higher crop yields, more growing cycles and helps lower production costs.

Isracann’s company highlights include the following:

  • Isracann is focused on becoming a premier low-cost cannabis producer in Israel and the EU.
  • The European cannabis market is expected to be worth 123 billion euros by 2028.
  • Isracann is developing a fully-funded 230,000-square-foot cultivation facility near Tel Aviv.
  • Once complete, the facility can produce up to 23,500 kilograms of cannabis annually.
  • The facility is being built to EU-GMP standards, a necessity for exporting cannabis to the EU.
  • Isracann is also pursuing IMC-GAP and GSP certification for the facility to ensure that the company can export its products.
  • Israel offers an optimal environment to grow cannabis as it is high in humidity, has ideal temperatures and receives, on average, 300 days of sunshine.
  • The hybrid nature of Isracann’s cultivation facility allows the company to effectively utilize Israel’s climate, reducing production costs and increasing yields.
  • Isracann is targeting low-cost production at its facility at only C$0.40 per gram.

Click here to see the educational profile for Isracann Biosciences and to request an investor presentation. 


Avicanna Inc. (the “ Company ” or “ Avicanna ”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) is pleased to announce that all of management’s nominees listed in the Company’s management information circular dated May 25, 2021 were elected as directors of the Company at Avicanna‘s annual general meeting of shareholders held on June 24, 2021 (the ” Meeting “). The detailed results of the vote for the election of directors held at the Meeting are set out below.

Keep reading... Show less

Quantum 1 Cannabis (CSE:QQ) announced its revenue for the third quarter of 2021 has increased by 672 percent and gross profit has increased by 463 percent compared with the same quarter in 2020. Quantum 1 Cannabis CEO Russ Rossi expounded on this exponential growth and what’s behind this remarkable leap. 

“We had an opportunity during our cannabis training to opt into some leases for cannabis retail. So we thought, let’s take a shot at this and see if we can use our experience with mobile location and supercharge. It paid off. It was a new game for everybody. It’s a lot of luck when opportunity meets preparation,” said Rossi. 

Quantum 1 Cannabis attributed the growth to high month-over-month sales coming from its flagship store in North Vancouver, improved demand for specialized “cottage-grown” sativa and indica products, continued training and hiring of best-of-breed staff and management to cater to consumer inquiries and expanded in-house technology for management of human resources, inventory and regulatory requirements. 

“Our plan is to have the maximum number of retail stores possible in British Columbia. We have 10 year leases on these stores, putting everything in on a solid pitch for the city council. I’m pretty confident that we’re going to have eight centers full blast in BC within six months,” explained Rossi. 

Quantum 1 Cannabis has signed a memorandum of understanding to acquire an approved municipal cannabis retail location in one of Vancouver’s most diverse neighborhoods at 41st Avenue and Cambie Street in Vancouver, British Columbia. The flagship location is expected to expand the company’s footprint in the Lower Mainland.

Watch the full interview with Quantum 1 Cannabis (CSE:QQ) CEO Russ Rossi above.

Keep reading... Show less

Process leads to standardized psychedelic extracts that are reproducible, scalable, cost-effective and commercially viable

Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce that its subsidiary Numinus Bioscience Inc. (“Numinus Bioscience”) has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for a process that dramatically increases the production of therapeutics for use in psychedelic-assisted psychotherapy.

Keep reading... Show less

Opening Marks Company’s 107th Retail Location Nationwide

Strategic Expansion Will Help Serve the State’s Rapidly Growing Cannabis Market

Keep reading... Show less

Ayurcann (CSE:AYUR) entered into a joint venture with Bazelet Group, Israel’s largest privately held medical cannabis company. Ayurcann CEO Igal Sudman shared the company’s excitement about bringing unique terpene-enriched medicinal cannabis to the Canadian marketplace. 

“Canada is a very closed-loop country, and the opportunity to bring a variety of different enhancement and technologically advanced products is very important to us. The relationship that we formed with Bazelet is going to enhance our offerings into the Canadian marketplace,” Sudman said. 

Bazelet has launched multiple lines of terpene-enriched cannabis oils; each one is specifically designed for various indications, symptoms and personal needs. The company’s terpene-enriched products are optimized for women’s health, for elderly population needs, for specific types of pains (muscle, joint, neuropathic) and for improved night sleep. 

According to Sudman, there are a lot of larger companies that have tried to do this, but none have been able to successfully bring innovation into the market. Ayurcann is rapidly forging partnerships with several companies worldwide, including Cannmart, Patient Choice and Kindred Partners.

“We’re growing the business, customer base, relationships and partnerships worldwide. We’re bringing the latest technology into Canada, and enhancing not only our company, but the investors’ value moving forward,” added Sudman. 

Watch the full interview with Ayurcann CEO Igal Sudman above.

Keep reading... Show less